Rajeshwari Sridhara - Concepedia

Author

Rajeshwari Sridhara

United States Food and Drug Administration

Also Known As

R Sridhara, Rajeshwari Sridhara

225

Publications

20.3K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research University of Maryland, Baltimore National Cancer Institute Center for Devices and Radiological Health

About

Rajeshwari Sridhara is an author at United States Food and Drug Administration specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	37	4.4K
2	Health Sciences	15	17	1.8K
3	Public Health	4	4	82
4	Education	1	1	448
5	Nursing	1	1	16

Rajeshwari Sridhara

Publications

11.1K

Citations

H-Index

Page 1

	Year	Citations
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara, The Oncologist Gefitinib 250OncologyCancer ManagementPharmacologyClinical Trials	2003	569
United States Food and Drug Administration Drug Approval Summary Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara, Clinical Cancer Research Gefitinib TherapyDrug PolicyCancer PharmacologyPharmacotherapyGefitinib Effectiveness	2004	500
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement Edward S. Kim, Suanna S. Bruinooge, Samantha Roberts, Journal of Clinical Oncology Eligibility CriteriaClinical EndpointAmerican SocietyEducationNeuro-oncology	2017	448
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets Martin H. Cohen, John R. Johnson, Yeh‐Fong Chen, The Oncologist	2005	434
United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy Robert C. Kane, Ann T. Farrell, Rajeshwari Sridhara, Clinical Cancer Research	2006	344
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer Laleh Amiri‐Kordestani, Gideon M. Blumenthal, Qiang Xu, Clinical Cancer Research Metastatic Breast CancerIndependent Review CommitteeBreast OncologyMedicineCancer Management	2014	336
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody V. Ellen Maher, Laura L. Fernandes, Chana Weinstock, Journal of Clinical Oncology	2019	336
Bortezomib for the Treatment of Mantle Cell Lymphoma Robert C. Kane, Ramzi Dagher, Ann T. Farrell, Clinical Cancer Research	2007	330
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2 Qin Ryan, Amna Ibrahim, Martin H. Cohen, The Oncologist	2008	303
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis Jennifer Gao, Joyce Cheng, Erik Bloomquist, The Lancet Oncology Metastatic Breast CancerBreast OncologyMedicinePharmacologyBreast Cancer	2019	288

Page 1